Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574020 | 0.95 | ADORA3 (0.66) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL20180024 | 0.90 | ADORA3 (0.72) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL13384988 | 0.88 | ADORA1 (0.71) | ADORA1ADORA2BADORA3ADORA2ARXFP1 | |
| SCHEMBL7169928 | 0.85 | ADORA1 (1.00) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL3950397 | 0.85 | ADORA1 (1.00) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL5993960 | 0.83 | ADORA3 (0.64) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL7733889 | 0.82 | PI4KA (0.64) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL31060441 | 0.82 | ADORA1 (1.00) | ADORA1ADORA2BADORA3ADORA2A | |
| SCHEMBL20180090 | 0.81 | ADORA3 (0.61) | ADORA1ADORA2BADORA3ADORA2AMEN1 | |
| SCHEMBL7734131 | 0.81 | ADORA3 (0.53) | ADORA1ADORA2BADORA3ADORA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576620-B2 | Measuring agonist stimulated (35S)GTP gamma S binding to G proteins by compound, measuring extent of agonist stimulated (35S)GTP gamma S binding to G proteins by a full adenosine A1 receptor agonist, selecting compounds with 65-95% binding | CV THERAPEUTICS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20010008883-A1 | Method of identifying partial adenosine A1 receptor agonists and their use in the treatment of arrhythmias | CV THERAPEUTICS, INC. | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008883-A1 | Method of identifying partial adenosine A1 receptor agonists and their use in the treatment of arrhythmias | ADORA1, ADORA3, ADORA2A | ADORA1 1/4885ADORA2B 4/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.